Press Releases

PRESS RELEASE October 19, 2017

Immune Pharmaceuticals Inc. Announces Pricing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants

October 19, 2017 09:00 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (“Immune”) (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the pricing of an underwritten public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and […]

Keep Reading

PRESS RELEASE October 18, 2017

Immune Pharmaceuticals Announces Presentation at The Liver Meeting 2017

Poster demonstrates activity of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis October 11, 2017 08:45 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the results of a study investigating the therapeutic […]

Keep Reading

PRESS RELEASE September 27, 2017

Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Results from six subjects demonstrate a large and statistically significant reduction in bullous pemphigoid activity despite aggressive prednisone tapering, with no serious adverse events. September 27, 2017 08:00 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today […]

Keep Reading

PRESS RELEASE August 29, 2017

Immune Pharmaceuticals Receives NASDAQ Letter

August 29, 2017 04:15 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) announced today that on August 23, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“Nasdaq”) that the Company no longer complies with the minimum stockholders’ equity requirement under NASDAQ Listing […]

Keep Reading

PRESS RELEASE August 28, 2017

Immune Pharmaceuticals Provides R&D and Business Update and Summary of Recent Financial Highlights

August 28, 2017 08:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune” or the “Company”) provided the following R&D and business update and summary of recent financial highlights. R&D Update Immune continues to focus on the development of its two core assets: (1) bertilimumab, a first in class, monoclonal antibody in Phase […]

Keep Reading

PRESS RELEASE August 19, 2017

Immune Pharmaceuticals Receives NASDAQ Letter

August 29, 2017 04:15 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) announced today that on August 23, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“Nasdaq”) that the Company no longer complies with the minimum stockholders’ equity requirement under NASDAQ Listing […]

Keep Reading

PRESS RELEASE August 14, 2017

Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer

August 14, 2017 08:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals (NASDAQ:IMNP) (the “Immune” or the “Company”) announced today that it has appointed Tony Fiorino, MD, PhD to the joint position of Chief Medical Officer and Chief Operating Officer. Dr. Fiorino will be responsible for all research and development and clinical and manufacturing activities […]

Keep Reading

PRESS RELEASE August 9, 2017

CYTOVIA Inc, IMMUNE Pharma’s Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic Properties of Its Lead Drug Ceplene® and Filing of a New Worldwide Patent

Additional potential in cancer immunotherapy with Ceplene in combination with Interleukin-15 (IL-15) August 09, 2017 09:30 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Cytovia, the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune”), a clinical stage biopharmaceutical company, today announced the publication of results showing favorable effects of its lead immunotherapeutic compound Ceplene® (histamine dihydrochloride) in cancer. […]

Keep Reading

PRESS RELEASE August 7, 2017

CYTOVIA Inc., IMMUNE Pharma’s Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene® in Chronic Myeloid Leukemia (CML)

Strengthens Intellectual property portfolio and expands potential clinical use and market opportunity August 07, 2017 09:27 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Cytovia, the oncology subsidiary of Immune Pharmaceuticals (NASDAQ:IMNP) (“Immune” or the “Company”), a clinical stage biopharmaceutical company, today announced the publication of new results supporting the benefits of its lead compound Ceplene® (histamine […]

Keep Reading